Effects of prasugrel, a novel P2Y12 inhibitor, in rat models of cerebral and peripheral artery occlusive diseases

European Journal of Pharmacology

Volumn 612, Issue 1-3, 2009, Pages 29-34

  Ogawa, Taketoshi ^a   Hashimoto, Masami ^a   Niitsu, Yoichi ^a   Jakubowski, Joseph A ^b   Tani, Yoshiro ^a   Otsuguro, Ken ichi ^a   Asai, Fumitoshi ^a   Sugidachi, Atsuhiro ^a  

^a DAIICHI SANKYO CO   (Japan)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

ADP; Antiplatelet agent; P2Y12 antagonist; Peripheral arterial occlusive disease; Platelet aggregation; Stroke; Thienopyridine

Indexed keywords

CLOPIDOGREL; LAURIC ACID; PRASUGREL; PURINERGIC RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BRAIN INFARCTION; COMMON CAROTID ARTERY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMORAL ARTERY; IRRADIATION; MALE; MIDDLE CEREBRAL ARTERY; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RAT; THROMBOEMBOLISM;

ANIMALS; CEREBRAL ARTERIAL DISEASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PERIPHERAL VASCULAR DISEASES; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P2; THIOPHENES;

EID: 65549139004     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.03.073     Document Type: Article

References (32)

1. Angiolillo D.J., Bernardo E., Sabaté M., Jimenez-Quevedo P., Costa M.A., Palazuelos J., Hernández-Antolin R., Moreno R., Escaned J., Alfonso F., Bañuelos C., Guzman L.A., Bass T.A., Macaya C., and Fernandez-Ortiz A. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J. Am. Coll. Cardiol. 50 (2007) 1541-1547
2. Antman E.M., Wiviott S.D., Murphy S.A., Voitk J., Hasin Y., Widimsky P., Chandna H., Macias W., McCabe C.H., and Braunwald E. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J. Am. Coll. Cardiol. 51 (2008) 2028-2033
3. Ashida S., Ishihara M., Ogawa H., and Abiko Y. Protective effect of ticlopidine on experimentally induced peripheral arterial occlusive disease in rats. Thromb. Res. 18 (1980) 55-67
4. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.D., Flather M.D., Haffner S.M., Hamm C.W., Hankey G.J., Johnston S.C., Mak K.H., Mas J.L., Montalescot G., Pearson T.A., Steg P.G., Steinhubl S.R., Weber M.A., Brennan D.M., Fabry-Ribaudo L., Booth J., Topol E.J., and CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New Engl. J. Med. 354 (2006) 1706-1717
5. Brandt J.T., Payne C.D., Wiviott S.D., Weerakkody G., Farid N.A., Small D.S., Jakubowski J.A., Naganuma H., and Winters K.J. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. 153 (2007) 66.e9-66.e16
6. Buonamici P., Marcucci R., Migliorini A., Gensini G.F., Santini A., Paniccia R., Moschi G., Gori A.M., Abbate R., and Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 49 (2007) 2312-2317
7. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
8. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., Leys D., Matias-Guiu J., Rupprecht H.J., and MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
9. Donnelly R., and Collinson D.J. Consensus on anti-platelet therapy in peripheral arterial disease: saving lives and limbs. Platelets 14 (2003) 403-406
10. Frelinger III A.L., Jakubowski J.A., Li Y., Barnard M.R., Fox M.L., Linden M.D., Sugidachi A., Winters K.J., Furman M.I., and Michelson A.D. The active metabolite of prasugrel inhibits ADP-stimulated thrombi-inflammatory markers of platelet activation: influence of other blood cells, calcium, and aspirin. Thromb. Haemost. 98 (2007) 192-200
11. Fukuuchi Y., Tohgi H., Okudera T., Ikeda Y., Miyanaga Y., Uchiyama S., Hirano M., Shinohara Y., Matsumoto M., and Yamaguchi T. A randomized, double-blind study comparing the safety and efficacy of clopidogrel versus ticlopidine in Japanese patients with noncardioembolic cerebral infarction. Cerebrovasc. Dis. 25 (2008) 40-49
12. Geisler T., and Gawaz M. Variable response to clopidogrel in patients with coronary artery disease. Semin. Thromb. Hemost. 33 (2007) 196-202
13. Goto J., Araki H., Otomo S., and Aihara H. A comparison of the effect of the Lipo PGE1 and other related compounds on experimental peripheral arterial occlusive disease in rats. Drugs Exp. Clin. Res. 12 (1986) 917-921
14. Hara H., Shimada H., Kitajima A., and Tamao Y. Effect of (±)-2-(dimethylamino)-1-[[o-(m-methoxyphenethyl) phenoxy]methyl]ethyl hydrogen succinate on experimental models of peripheral obstructive disease. Arzneimittelforschung 41 (1991) 616-620
15. Hochholzer W., Trenk D., Bestehorn H.P., Fischer B., Valina C.M., Ferenc M., Gick M., Caputo A., Büttner H.J., and Neumann F.J. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol. 48 (2006) 1742-1750
16. Jakubowski J.A., Winters K.J., Naganuma H., and Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc. Drug Rev. 25 (2007) 357-374
17. Lee J.H., Park S.Y., Lee W.S., and Hong K.W. Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats. Neurol. Res. 27 (2005) 483-492
18. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., Novikov I., Pres H., Savion N., Varon D., and Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 109 (2004) 3171-3175
19. Niitsu Y., Jakubowski J.A., Sugidachi A., and Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin. Thromb. Hemost. 31 (2005) 184-194
20. Niitsu Y., Sugidachi A., Ogawa T., Jakubowski J.A., Hashimoto M., Isobe T., Otsuguro K., and Asai F. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. Eur. J. Pharmacol. 579 (2008) 276-282
21. Ogawa T., Sugidachi A., Tanaka N., Fujimoto K., and Asai F. Effects of R-102444, an orally active 5-HT2A receptor antagonist, in rat models of peripheral vascular disease. Vascul. Pharmacol. 41 (2004) 7-13
22. Sacco R.L., Diener H.C., Yusuf S., Cotton D., Ounpuu S., Lawton W.A., Palesch Y., Martin R.H., Albers G.W., Bath P., Bornstein N., Chan B.P., Chen S.T., Cunha L., Dahlöf B., De Keyser J., Donnan G.A., Estol C., Gorelick P., Gu V., Hermansson K., Hilbrich L., Kaste M., Lu C., Machnig T., Pais P., Roberts R., Skvortsova V., Teal P., Toni D., Vandermaelen C., Voigt T., Weber M., Yoon B.W., and PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 359 (2008) 1238-1251
23. Siller-Matula J., Schrör K., Wojta J., and Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb. Haemost. 97 (2007) 385-393
24. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G., Jukema J.W., and Huisman M.V. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J. 154 (2007) 221-231
25. Sugidachi A., Asai F., Ogawa T., Inoue T., and Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br. J. Pharmacol. 129 (2000) 1439-1446
26. Sugidachi A., Asai F., Yoneda K., Iwamura R., Ogawa T., Otsuguro K., and Koike H. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br. J. Pharmacol. 132 (2001) 47-54
27. Uemura T., Takamatsu H., Kawasaki T., Taniguchi M., Yamamoto E., Tomura Y., Uchida W., and Miyata K. Effect of YM-254890, a specific Galphaq/11 inhibitor, on experimental peripheral arterial disease in rats. Eur. J. Pharmacol. 536 (2006) 154-161
28. Umemura K., Ishihara H., and Nakashima M. Anti-platelet effects of clopidogrel in rat middle cerebral artery thrombosis model. Thromb. Res. 80 (1995) 209-216
29. Wallentin L., Varenhorst C., James S., Erlinge D., Braun O.O., Jakubowski J.A., Sugidachi A., Winters K.J., and Siegbahn A. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J., 29 (2008) 21-30
30. Wiviott S.D., Trenk D., Frelinger A.L., O'Donoghue M., Neumann F.J., Michelson A.D., Angiolillo D.J., Hod H., Montalescot G., Miller D.L., Jakubowski J.A., Cairns R., Murphy S.A., McCabe C.H., Antman E.M., Braunwald E., and PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation, 116 (2007) 2923-2932
31. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., Neumann F.J., Ardissino D., De Servi S., Murphy S.A., Riesmeyer J., Weerakkody G., Gibson C.M., Antman E.M., and TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357 (2007) 2001-2015
32. Wiviott S.D., Braunwald E., McCabe C.H., Horvath I., Keltai M., Herrman J.P., Van de Werf F., Downey W.E., Scirica B.M., Murphy S.A., Antman E.M., and TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 371 (2008) 1353-1363